Work­ing to get its pain R&D strat­e­gy back on track, Acel­Rx steps clos­er to an FDA pitch

Acel­Rx has de­liv­ered an­oth­er pos­i­tive piece of the Phase III puz­zle for ARX-04, its un­der-the-tongue ap­pli­ca­tion of a 30 mcg dose of the pow­er­ful opi­oid sufen­tanil de­signed to de­liv­er a jolt of fast pain re­lief.

Ex­pand­ing on an im­prove­ment in pain scores al­ready record­ed for the first co­hort of 40 in­jured pa­tients who turned up at the ER and re­ceived a sin­gle dose of ARX-04, the Red­wood City, CA-based biotech says that it record­ed a slight­ly bet­ter out­come for a small group of 36 more pa­tients who were green-light­ed for mul­ti­ple ap­pli­ca­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.